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Abstract 
Advances in the understanding of the neurobiology of fear extinction resulted in the 
development of d-cycloserine (DCS), a partial glutamatergic N-methyl-D-aspartate agonist, as 
an augmentation strategy for exposure treatment. We review a decade of research that has 
focused on the efficacy of DCS for augmenting the mechanisms (e.g., fear extinction) and 
outcome of exposure treatment across the anxiety disorders. Following a series of small-scale 
studies offering strong support for this clinical application, more recent larger-scale studies have 
yielded mixed results, with some showing weak or no effects. We discuss possible explanations 
of the mixed findings, pointing to both patient and session (i.e., learning experiences) 
characteristics as possible moderators of efficacy, and offer directions for future research in this 
area. We also review recent studies that have aimed to extend the work on DCS augmentation 
of exposure therapy for the anxiety disorders to DCS enhancement of learning-based 
interventions for addiction, anorexia nervosa, schizophrenia, and depression. Here, we attend to 
both DCS effects on facilitating therapeutic outcomes and additional therapeutic mechanisms 
beyond fear extinction (e.g., appetitive extinction, hippocampal-dependent learning).  
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Text 
Introduction 
One of the particular achievements of translational research has been the 
documentation of the importance of N-methyl-d-aspartate (NMDA) glutamatergic receptor to 
extinction learning, and the application of its partial agonist, d-cycloserine (DCS), as a strategy 
to aid the consolidation of extinction learning in animal models (1), and subsequently in human 
clinical applications (2).  It is well accepted that NMDA receptors are involved in the acquisition, 
consolidation, and retrieval of extinction memory (3, 4).  DCS activates NMDA receptors by 
binding with their glycine binding sites, enhancing the conditions for long term potentiation, and 
consequently, enhancing memory (2).   
 When DCS is administered orally to augment exposure therapy, it may be exerting its 
effects on multiple regions of interest at different points in the extinction learning process.  
Identification of DCS effects on specific brain regions is aided by animal models of exposure 
therapy (i.e., extinction training) investigating region-specific DCS administrations.  This work 
has supported efficacy for DCS augmentation when infused into each of the major regions 
identified in fear extinction circuits –amygdala, hippocampus, and prefrontal cortex (5-10), 
including the infusion of DCS after extinction training (7), supporting the role of DCS in aiding 
the consolidation of extinction learning.  
The initial translation of DCS augmentation into clinical application (11) was followed by 
a number of small placebo-controlled trials across the anxiety disorders that often reported large 
effects for the advantage of DCS over placebo for augmenting a small number of exposure 
sessions (12, 13). Yet, as research on DCS augmentation progressed to more diverse protocols 
and large multicenter trials, the effect size for its benefit began to falter (14-16; see Table 1).  
Sequential meta-analytic reviews help document this decline.  In 2008, Norberg et al. (15), 
reported an effect size of d = .60 for 8 clinical trials of DCS, in 2012, Bontempo et al. (14), 
reported an effect size d =.46 for 9 trials, and in 2014, Rodrigues (16) reported a small to 
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moderate effect (13 studies, d = .34, 95% Confidence Interval: .34 to .54) for the advantage of 
DCS vs. placebo augmentation of exposure-based treatment.  In addition to some negative 
trials in the anxiety-related disorders (17), failures appeared in other applications, such as the 
application of DCS augmentation to cue exposure treatments of substance use disorders (18, 
19). In the context of these faltering estimates of the DCS augmentation efficacy, however, 
important moderators were discovered (20, 21), enough so that guidance on judicious use of 
DCS for augmentation appears to be at hand. This review is concerned with the mechanism, 
moderators, and future directions for the application of DCS as an augmenting agent for CBT.  
A New Approach to Combination Treatment 
At the outset, it is important to consider the context in which DCS augmentation first 
emerged into the anxiety treatment literature. Decades of effort have been applied to examine 
the benefit of combining pharmacotherapy and cognitive-behavior therapy for anxiety disorders, 
and, as meta-analytic reviews attest, the result has often been disappointing – with limited acute 
advantages that are often lost over follow-up intervals (22-24). Moreover, concerns have arisen 
that antidepressant or benzodiazepine medications, while offering anxiolytic benefit on their  
own, may also hinder the short-term and long-term efficacy of exposure-based treatments (25, 
26).  In the context of these frustrating results, augmentation of CBT with DCS represented an 
important innovation in the application of pharmacotherapy to combined treatment.  Rather than 
directly targeting anxiolysis, DCS was instead used to enhance the consolidation of the 
therapeutic learning offered by CBT. What are the likely effects of memory enhancement of this 
kind?  First, and most obviously, DCS may speed the onset of benefit from CBT by allowing 
more to be learned/retained from fewer sessions.  Second, DCS may act as a rescue strategy 
for poor extinction learners, helping them achieve benefits that they may not be able to achieve 
without the help of memory enhancement. 
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The Nature of DCS Augmentation Benefits 
Initial studies of DCS augmentation did little to clarify which of these two potential 
actions might be operative. In animal and the initial human paradigms investigating DCS 
augmentation (6, 11, 27) the number of extinction trials/sessions were reduced, often by half or 
more, to ensure that extinction would be incomplete. This was done to avoid floor effects that 
would obscure DCS augmentation of extinction outcomes. Also, in human application, DCS is 
most often given in a limited number of individual, weekly doses, based on concerns about the 
development of tolerance that may result from more frequent or prolonged use (28-30). For 
example, Hofmann et al. (12) examined DCS augmentation in the context of only five total 
sessions of CBT.  The first session was devoted to presenting the model of treatment and DCS 
(vs. placebo) was used on the remaining four sessions that emphasized exposure to social 
challenges (e.g., public speaking). For initial application to panic disorder, we used two sessions 
to help our patients orient to treatment and the interoceptive (internal cue) exposure used in the 
protocol, and then provided three sessions of DCS (or placebo) combined with 90-minute 
exposure sessions (13). These brief 5-session protocols stand in contrast to the 12- to 16-
session protocols of treatment suggested in manualized treatment protocols (31-34).  Both of 
these placebo-controlled trials showed strong benefit from DCS augmentation. Yet, with such a 
brief protocol of treatment, the outcome advantage at endpoint could have simply reflected a 
speeding of treatment effects rather than an overall enhancement of outcome relative to that 
which could be achieved with a standard protocol of CBT (see Figure 1).  Additional trials of 
DCS enhancement appear to show that the acceleration of treatment gains may be the 
dominant effect of DCS enhancement, at least for standard clinical samples of patients.  For 
example, Kushner et al. (35) was the first to show that with repeated exposure sessions, 
exposure alone can catch up to the early advantage provided by DCS augmentation (36). This 
apparent “catch up” effect has also been shown in animal models.  Ren and colleagues (9) 
found that DCS facilitated the speed of improvement in extinction retention, but that animals 
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undergoing saline augmentation caught up to the DCS group by the third out of five days of 
extinction training.    
Comparisons between trials also show the apparent loss of an advantage for DCS 
augmentation in the context of additional exposure sessions. Both Hofmann et al. (12) and 
Guastella et al. (37) showed strong efficacy for DCS augmentation for social anxiety disorder 
following 5 sessions of treatment, but then Hofmann et al. (38) showed no advantage in 
endpoint response or remission rates for DCS following 12 sessions of treatment, but faster 
response earlier in treatment.  Likewise, Otto (13) showed a clear advantage for DCS 
augmentation for panic disorder following 5 sessions of treatment, but Siegmund (39) showed 
strong improvement overall with no group differences following 11 sessions of treatment, but a 
trend toward a speeding of treatment response for more severe patients receiving DCS vs. 
placebo augmentation. It is important to note that a faster treatment response can have far 
reaching effects.  In addition to the more rapid reduction of the distress and disability associated 
with anxiety disorders, more efficient treatment also means a reduction in limited treatment 
resources (CBT therapist time), lower cost of treatment, less barrier to ongoing treatment (e.g., 
time off work, travel to sessions), and potentially less dropout (35) as treatment gains are 
realized more quickly (40).   
In addition to these important effects on the efficiency of treatment, it remains an open 
question whether DCS has additional rescue effects, helping select individuals who have 
difficulty achieving fear reduction from exposure, despite repeated sessions.  For these 
individuals, DCS may provide crucial enhancement of learning, providing a response when it 
would otherwise be unlikely (Figure 1).  For individuals who are slow responders to CBT or who 
are otherwise unable to consolidate the safety learning from exposure, augmentation with DCS 
may set them on a course for fuller response by the end of a standard course of treatment.  For 
example, in a trial of 67 outpatients with PTSD undergoing up to 10 sessions of CBT 
(augmented by DCS or placebo), de Kleine et al. (41) did not find an overall augmentation effect 
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at treatment endpoint, but exploratory session-by-session analyses indicated that DCS was 
more beneficial for individuals who had more severe pretreatment PTSD and needed longer 
treatment. At present, only pilot studies inform the application of DCS augmentation to 
treatment-refractory samples (see Supplemental Information). For example, an open report of 
two cases of patients with obsessive-compulsive disorder (OCD) who were unresponsive to a 
program of exposure and response prevention, documents improvements after additional 
sessions augmented with DCS (42). Likewise, Farrell and colleagues (43) found superior 
outcome for DCS vs. placebo augmentation at 1-month follow-up in a small (N=17) treatment-
refractory pediatric OCD sample undergoing exposure and response prevention treatment.  
These findings suggest that, in addition to a clear role in speeding treatment, DCS 
augmentation may have a role in rescuing inadequate treatment response in selected 
treatment-refractory samples.   
Identification of the scope of such rescue-treatment applications is made difficult by the 
relative absence of research linking learning impairments to outcome in CBT. Cognitive and 
extinction-learning deficits are ubiquitous in adults with anxiety and mood disorders (44, 45), but 
we are aware of only three randomized treatment studies that link cognitive deficits to poorer 
CBT outcome (46-48).  Research is needed to clarify whether DCS can rescue treatment 
outcome for these individuals, including research on whether cognitive deficits influence: (a) 
within-session learning of extinction, (b) retention of extinction across sessions, or (c) both. 
These distinctions are relevant because it is the retention of extinction learning that appears to 
be the primary domain of DCS augmentation (7).   
In summary, our interpretation of the DCS clinical anxiety literature to date is that effects 
appear to be achieved primarily in terms of a speeding of clinical outcomes. When the number 
of CBT sessions provided is low, this speeding of treatment is reflected by large effects at 
treatment endpoint. However, when a greater number of exposure sessions are provided--
providing ample opportunities for learning without the aid of memory enhancement--only subtle 
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differences are observed for the full sample at study endpoint, despite an apparent advantage 
for DCS augmentation early in treatment.  
Moderators of DCS Augmentation 
There is also strong evidence for variable DCS augmentation efficacy based on the 
quality of learning within exposure sessions. Because DCS is targeted to enhancing the degree 
of therapeutic learning achieved from CBT, any positive effects of DCS on exposure therapy 
outcome should be dependent on the degree to which adequate extinction learning has 
occurred at the time the drug is active (2, 8).  Consistent with this account, animal studies 
indicate that augmentation effects are achieved only with animals that demonstrate extinction at 
the time DCS is administered (49, 50). Likewise, there is now evidence extending this effect to 
the clinic. Smits et al. (21) examined whether the clinical benefit of DCS augmentation was a 
function of response to the exposure session. They found that DCS offered an advantage only 
for individuals who had achieved low fear by the end of the CBT session. In contrast, placebo 
augmentation offered greater benefit than DCS augmentation for patients with elevated fear at 
the end of the session. This effect was replicated for a large-scale trial of DCS augmentation for 
social anxiety disorder. Reanalysis of overall limited benefits for DCS (38) revealed that patients 
who reported low fear at the end of a CBT session showed a clear advantage for DCS vs. 
placebo augmentation, and an opposite pattern emerged for those with high fear at the end of a 
CBT session (20). This interaction effect was evident from one CBT session to the next, and 
was also evident for predicting clinical outcomes at post-treatment.  These moderating effects of 
exposure success were indexed by fear ratings provided by patients at the conclusion of 
exposure, and were not better accounted for by the degree of within-session change in fear 
ratings. It is noteworthy that the moderating effect for end fear was further replicated for different 
putative extinction enhancers, yohimbine and methylene blue (51, 52), raising confidence in the 
generalizability of this effect, and supporting the notion that the degree of benefit offered by 
these augmenting agents is dependent on adequate learning from exposure. If the exposure 
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inadequately achieves within-session extinction, then there is little therapeutic benefit available 
for enhancement via greater memory consolidation. Indeed, combining DCS with less-than-
successful exposure sessions has been used to explain data showing impaired treatment 
response with DCS relative to placebo augmentation (17). 
These findings are also consistent with studies showing that DCS not only augments 
extinction learning but can also enhance reconsolidation of fear memories in animals and 
humans (8, 53-55). Therefore, if fear does not decrease during exposure, fear memory 
reconsolidation may occur and DCS may facilitate this counter-therapeutic process. In other 
words, DCS appears to make “good” exposures better and “bad” exposures worse (55). 
Accordingly, the nature of the disorder under treatment (e.g. simple phobia vs. complex PTSD) 
and patient variables (e.g. personality traits, cognitive flexibility or impairment) may influence the 
degree of in-session extinction learning, and hence DCS augmentation effects. These 
considerations are apt as the field confronts current failures of DCS to successfully augment 
exposure therapy for PTSD, with a recent null result reported by Rothbaum et al. (56) joining an 
earlier unsuccessful trial by Litz and associates (17). There is some evidence that these null 
results may again be moderated by exposure success; Rothbaum and associates (56) found 
that DCS-augmentation showed a specific advantage for the stronger extinction learners within 
their sample.  As such, successful application of DCS augmentation to PTSD may require 
particularly judicious use.  
One strategy to achieve such judicious use is to administer DCS post- instead of pre-
session, limiting the administration to exposure sessions that are characterized by low end fear 
(adequate extinction learning; exposure success). Support for tailored post-session 
administration of DCS comes from animal studies that have documented success with post-
session DCS administration up to two hours following training (7, 57). This stands in contrast to 
the typical administration strategy for DCS augmentation for exposure therapy; DCS is typically 
administered orally one or more hours before an exposure session to achieve adequate 
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concentrations of DCS centrally by the conclusion of the exposure session, consistent with 
expectation of peak blood levels two hours after oral administration (58).  We are aware of only 
two studies investigating post-session administration in humans. Tart et al. (59) investigated 
post-session DCS administration in a sample of acrophobic adults treated with two sessions of 
virtual reality exposure therapy. Mataix-Cols et al. (60) investigated this strategy in 27 youth with 
OCD treated with 10 sessions of CBT.  Both studies reported overall null results.  However, 
reanalysis of the null result for the study by Tart et al. (59) revealed significant DCS effects 
when exposure success was treated as a moderator (21); thereby showing that post-session 
administration can work in human applications.  Research by our group is now underway to 
further test the adequacy of judicious post-treatment application of DCS augmentation (61).  
Recent research also raises the possibility that other medication use may alter DCS 
augmentation effects.  In a post-hoc analysis of an OCD trial, Andersson and associates (62) 
observed an interaction between DCS and antidepressant medication; DCS was found to be 
superior to placebo augmentation only in individuals who were free of antidepressant 
medication.  It is not clear whether this effect is due to direct effects of antidepressants or to 
other selection factors that led this subsample of patients to be on medication. Nonetheless, 
there is preliminary evidence for similar attenuation of DCS effects by chronic antidepressant 
pretreatment in an animal model (30) as well as evidence that antidepressant pretreatment can 
impair extinction learning (25, 26), thereby attenuating the within-session learning needed for 
beneficial DCS augmentation.  As such, future studies will need to evaluate whether there are 
differences in within-session extinction learning vs. between-session retention in these 
medicated individuals. 
Exposure Efficacy and DCS Augmentation of Addiction Treatment 
 Attending to the adequacy of extinction learning can also help clarify the variable results 
observed for the application of DCS augmentation to addiction treatment. Despite encouraging 
evidence from animal models of addiction (63-65), the human literature on DCS augmentation of 
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cue exposure therapy (CET) for substance use has been marked by more negative than positive 
findings (66; see Table 1).  Early positive DCS augmentation results for addiction treatment were 
reported by Santa Ana (67) for smokers randomized to DCS or placebo in combination with two 
sessions of CET. In a second study, Kamboj et al. (18) examined DCS vs. placebo augmentation 
of 2 sessions of cue exposure in smokers and reported no benefit on core outcomes. Likewise, 
Yoon and associates (68) reported no benefit for DCS in 29 cocaine-dependent cigarette 
smokers undergoing CET in a virtual reality environment. One trial reported an increase in 
cocaine craving with DCS vs. placebo (19). In trying to understand these mixed findings, 
attention has been placed on issues of sample size, dose and timing of DCS administration, and 
participant and design characteristics (66).  
In addition, attending to the adequacy of CET sessions for reducing craving and/or the 
presence of other sensitizing/conditioning experiences can help clarify the variable results within 
the DCS addiction literature.  First, there has been relatively poor control over sensitizing 
experiences. For example, both the Yoon et al. (68) and Kamboj et al. (18) studies of smoking 
cessation provide data indicating that participants were smoking around the study sessions, 
perhaps renewing the association between smoking cues and nicotine reward at times proximal 
to DCS administration.  DCS has a half-life of approximately 10 hours (69); smoking during this 
period may lead to reconditioning and should attenuate beneficial effects of DCS augmentation 
of CET. Second, of the studies reporting within-session extinction results, those that provided 
evidence of inconsistent or inadequate within-session extinction also reported null affects for 
DCS (18, 70, 71). Conversely, one of two studies reporting consistent reductions in cravings 
across individual trials within the exposure session found the expected DCS augmentation 
benefits (cf., 67, 72).   
 To minimize opportunity for re-establishing cue-drug reward associations proximal to 
DCS administration, we recommend studying DCS augmentation for drug use conditions in a 
relapse prevention model, randomizing only participants who are successfully abstinent 
Running head: D-CYCLOSERINE AUGMENTATION OF EXTINCTION LEARNING  Otto  12 
 
(NCT01399866). Likewise, a recent study of alcohol dependence examined DCS augmentation 
of CET primarily during the protective environment of inpatient treatment (73); the neuroimaging 
results supported DCS augmentation of CET for alcohol-associated cues. Finally, consistent 
with recommendations (70) for examining CET enhancement only in individuals shown to be 
reactive to the substance cue, MacKillop et al. (74) found beneficial effects of DCS 
augmentation on alcohol cue elicited cravings.  These recent studies suggest that DCS 
augmentation may indeed offer benefit to CET for addictions, provided that cue relevance, 
adequate cue exposure, and protection from sensitizing experiences are managed. 
Application to Exposure Therapy for Anorexia Nervosa 
 Following documentation that exposure to feared foods can aid in weight restoration 
among individuals with anorexia nervosa (75), Levinson and associates (76) conducted a small 
(N=36) trial investigating the augmenting effects of DCS on this exposure.  In this randomized 
trial, four exposure sessions were completed over a two-week period, with DCS or placebo 
given prior to the first three sessions.  Those individuals who received DCS achieved 
significantly higher weight gain than those in the placebo group.  Additional research is needed 
to confirm these findings, and investigate whether the degree of anxiety reduction during eating 
is meaningfully linked to DCS augmentation effects, and whether, like the application of DCS to 
anxiety disorders (20-21), judicious use of DCS might be warranted. 
DCS Augmentation in the Treatment of Depression  
Our research team is now seeking to extend DCS augmentation to CBT that does not rely 
on extinction learning for its therapeutic effects.  The animal literature is notable for positive 
DCS augmentation effects for hippocampal-dependent learning tasks (53, 77-79), but similar 
findings have yet to be reliably demonstrated in humans. Otto et al. (80) found no benefit for 
50mg of DCS for augmenting verbal and nonverbal declarative learning in healthy participants.   
Yet, Onur et al. (81) found that a single 250mg dose of DCS facilitated hippocampal-dependent 
declarative learning, and suggested that DCS effects on hippocampal functioning may be dose 
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dependent, requiring a 250mg dose rather than the 50mg that is sufficient for augmentation of 
extinction learning. Of note, retention over time was not assessed by Onur et al. (81), and it is 
the session-by-session promotion of therapeutic learning that has been of value for the 
treatment of anxiety disorders.  Investigation of whether 250 mg can enhance retention of 
therapeutic content from CBT for depression is now underway (NCT02376257). 
Failures of Human De Novo Fear Extinction Paradigms 
 Despite the success of DCS augmentation for the treatment of clinical fears in humans, 
and the success of DCS augmentation in de novo fear extinction models in animals (d = 1.19, 
20 studies) (15), de novo fear conditioning models have generally failed in human work (54, 82-
84). Grillon (85) has offered an important accounting of these effects, suggesting that the failure 
of DCS augmentation in these human paradigms may be due to the reliance on higher-order 
conditioning. Higher-order conditioning is slow and explicit and relies less on limbic activation 
and more on hippocampal structures, whereas lower-order conditioning is automatic and implicit 
and relies more on limbic activation and less on hippocampal structures.  Grillon (85) argues 
that de novo fear conditioning in animals as well as clinical fears in humans reliably activate a 
lower-order learning mechanism as the unconditioned stimulus (UCS) is interpreted as life 
threatening and triggers the automatic flight or fight response and limbic activation. In contrast, 
de novo fear conditioning in humans activates higher-order associative processes in part 
because the frequently milder (e.g., self-selected) UCSs used in the laboratory are not 
perceived as life threatening and does not activate the automatic fight or flight response.  In 
addition, humans enter the laboratory with expectations and conscious thought; their 
conditioned response is somewhat reliant on higher-order cognition as it is influenced by their 
awareness of the contingency between the CS and UCS.  As noted above, there is only limited 
evidence for DCS-enhancement of hippocampal-dependent memories in humans, with initial 
suggestion that successful DCS augmentation may require a higher dose of DCS than typically 
used (81).  
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Grillon (85) further proposes that DCS, at least at the dose typically used, is more 
effective for lower-order conditioned fears and acts on lower-order learning during exposure 
therapy for clinical fears. If this is accurate, this would mean that de novo fear conditioning will 
not be influenced by DCS, unless a particularly strong UCS is used.  This suggests that caution 
is warranted when interpreting failures of DCS augmentation of extinction when applied to 
nonclinical or de novo fears (82, 83), and indicates that de novo fear conditioning paradigms in 
humans may provide a poor model for studying the potential of DCS augmentation benefits for 
clinical anxiety disorders.  
Summary  
 The last decade of research has established DCS augmentation of exposure therapy as 
potentially valuable strategy for accelerating treatment response in the anxiety disorders.  As a 
memory augmentation strategy, DCS relies on effective exposure interventions for efficacy; 
without effective fear reduction in session, there appears to be no beneficial therapeutic memory 
to enhance.  As such, judicious application of DCS to the most efficacious exposure sessions is 
becoming the new model for applying DCS in the anxiety disorders.  In the same way, the 
failure of DCS augmentation for cue exposure for substance use disorders may be a result of 
inadequate extinction or subsequent sensitizing experiences.  Recent applications of DCS to 
substance use disorders suggest that these issues may be addressed by applying DCS 
augmentation of cue exposure during a relapse prevention phase or in inpatient settings where 
sensitization experiences proximal to DCS dosing can be avoided.  Ongoing research is also 
investigating whether DCS can be applied to CBT that does not rely on exposure interventions. 
Ongoing work in depression will provide initial evidence whether DCS can be applied 
successfully to enhancing benefits from cognitive restructuring interventions. 
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Figure Legends 
Figure 1. Model of DCS effects showing in Panel 1 a clear advantage when few sessions of 
exposure are provided (dark bars), but providing little benefit over full length treatment (stacked 
outcomes), and in Panel 2, rescuing treatment effects in individuals who a poor responders to 
exposure alone.  In both panels, initial exposure sessions are represented by dark bar sections, 
and the additional sessions characterizing standard treatment lengths are represented by the 
stacked gray-scale sections.  Trials using limited sessions only do not allow differentiation 
between speeded treatment and rescued treatment outcomes. Rescued treatment outcomes (if 
they occur) should be more evident when treatment-resistant samples are selected.  
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Table 1. Placebo-controlled studies of DCS to augment exposure therapy in adults with anxiety spectrum disorders, 
addiction, schizophrenia, or anorexia nervosa. 
Publication 
Sample Size 
Randomized Condition 
# of Total 
Sessions / 
Exposure 
Sessions / 
DCS 
administered 
DCS 
Dose 
(mg) 
Description of 
Findings 
Anxiety 
Spectrum           
Ressler 2004 
(11) 
27 Specific phobia 2/2/2 50 or 
500 
DCS (50mg and 
500mg combined) 
group displayed 
significantly greater 
improvement than 
the PBO group on all 
main outcome 
measures at post-
treatment and 3-
month follow up. No 
significant difference 
between 50mg or 
500mg DCS groups.  
Hofmann 2006 
(12) 
32 Social anxiety disorder 5/4/4 50 DCS group displayed 
significantly greater 
improvement than 
the PBO group on 
2/3 outcome 
measures at post-
treatment and 1-
month follow up 
(medium-large 
effects). 
Guastella 2007 
(82), study 1 
63 Spider-fearful 1/1/1 50 No differences in 
improvement 
between DCS and 
PBO group on all 
outcomes at post-
treatment or 3.5-
week follow up 
Guastella 2007 
(82), study 2 
37 Spider-fearful 1/1/1 50 or 
500 
No differences in 
improvement 
between DCS and 
PBO group on all 
outcomes at post-
treatment or 3.5-
week follow up 
Kushner 2007 
(35)  
32 Obsessive-compulsive 
disorder 
10/10/10 125 No differences in 
improvement 
between DCS and 
PBO group on all 
outcomes measures 
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at post-treatment and 
3-month follow up. 
Some evidence of 
faster improvement 
and lower dropout. 
Storch 2007 
(86) 
24 Obsessive-compulsive 
disorder 
12/12/12 250 No differences in 
improvement 
between DCS and 
PBO group on main 
outcome measures at 
post-treatment.   
Guastella 2008 
(37) 
56 Social anxiety disorder 5/4/4 50 DCS group displayed 
significantly greater 
improvement than 
the PBO group on 
4/5 outcome 
measures at post-
treatment and 1-
month follow up 
(mostly medium 
effects). 
Wilhelm 2008 
(87) 
23 Obsessive-compulsive 
disorder 
10/10/10 100 No differences in 
improvement 
between DCS and 
PBO group on main 
outcome measures at 
post-treatment and 1-
month follow up.  
Some evidence of 
faster improvement 
and improvement in 
depressive 
symptoms. 
Reanalysis indicated 
significant faster 
response for 
participants 
receiving DCS (88). 
Otto 2010 (13) 31 Panic disorder 5/4/3 50 DCS group displayed 
significantly greater 
improvement than 
the PBO group on all 
main outcome 
measures at post-
treatment and 1-
month follow up 
(large effects). 
Seigmund 2011 
(39) 
44 Panic disorder, Agoraphobia 8/3/3 50 No differences in 
improvement 
between DCS and 
PBO group on main 
outcome measures at 
post-treatment and 1-
month follow up. 
Some evidence of 
faster improvement 
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for more severe 
patients.   
De Kleine 2012 
(41) 
67 Posttraumatic stress disorder 10/9/9 50 No differences in 
improvement 
between DCS and 
PBO group on main 
outcome measures at 
post-treatment and 3-
month follow up; 
some evidence of 
higher post-treatment 
response rate. Some 
evidence of benefit 
for participants with 
severe pretreatment 
symptoms who 
needed longer 
treatment. 
Litz 2012 (17) 26 Posttraumatic stress disorder 6/4/4 50 PBO group displayed 
significantly greater 
improvement than 
DCS group on all 
main outcome 
measures at post-
treatment.  
Nave 2012 (89) 20 Specific phobia 1/1/1 50 No differences in 
improvement 
between DCS and 
PBO group on main 
outcome measures at 
post-treatment. Some 
evidence of faster 
improvement. 
Tart 2013 (59) 29 Specific phobia 2/2/2 50a No differences in 
improvement 
between DCS and 
PBO group on main 
outcome measures at 
post-treatment or 1-
month follow up. 
Evidence of 
exposure success as 
moderator. 
Reanalysis indicated 
significant greater 
DCS benefits for 
participants 
achieving low fear 
during exposure 
sessions (21). 
Hofmann 2013 
(38) 
169 Social anxiety disorder 12/5/5 50 No differences 
between DCS and 
PBO in completion, 
response, and 
Running head: D-CYCLOSERINE AUGMENTATION OF EXTINCTION LEARNING  Otto  30 
 
remission rates and 
post-treatment and 1, 
3, 6-month follow 
up. Evidence of 
faster (24-33%) 
improvement. 
Reanalysis indicated 
significant greater 
DCS benefits for 
participants 
achieving low fear 
during exposure 
sessions (20). 
Rothbaum 
2014 (56) 
106 Posttraumatic stress disorder 6/5/5 50 No differences in 
improvement 
between DCS and 
PBO group on main 
outcome measures at 
post-treatment or 3, 
6, 12-month follow 
up. Between-session 
extinction learning 
was a treatment-
specific enhancer of 
outcome for DCS 
group. 
Andersson 
2015 (62) 
128 Obsessive-compulsive 
disorder 
12/5/5 50 No differences 
between DCS and 
PBO in main 
outcome measures at 
post-treatment and 3-
month follow up. 
Evidence of 
significant 
interaction of DCS 
effects with 
antidepressant 
medication. 
Addiction           
Santa Ana 2009 
(67) 
25 Nicotine dependence 2/2/2 50 DCS group displayed 
significantly greater 
improvement than 
PBO group on 3 out 
of 7 main outcomes 
at post-treatment and 
1-week follow up 
(large effect at 
follow up). 
Kamboj 2011 
(72) 
40 Heavy drinkers 2/2/2 125 No differences in 
improvement 
between DCS and 
PBO group on main 
outcome measures at 
two sessions or 
follow up ~4 days 
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later. 
Watson 2011 
(70) 
16 Alcohol dependence 3/3/2 250 No differences in 
improvement 
between DCS and 
PBO group on main 
outcome measures at 
all 3 sessions. 
Hofmann 2012 
(71) 
20 Heavy drinkers 3/3/3 50 No differences in 
DCS and PBO group 
on most outcomes. 
Some evidence of 
poorer outcomes in 
DCS group than 
PBO group at first of 
2 post-treatment test 
sessions. 
Kamboj 2012 
(18) 
32 Heavy smokers 2/2/2 125 No differences in 
improvement 
between DCS and 
PBO group on main 
outcome measures at 
post-treatment or 2-
week follow up.  
Price 2013 (19) 32 Cocaine dependence 3/3/3 50 No differences in 
improvement 
between DCS and 
PBO group on main 
outcome measures at 
post-treatment. Some 
evidence of 
significantly poorer 
session-specific 
outcomes and 5-12 
day follow up 
outcomes in DCS 
group.  
Yoon 2013 (68) 47 Cocaine and nicotine 
dependence 
12/12/4 50 No differences in 
improvement 
between DCS and 
PBO group on main 
outcome measures at 
post-treatment or 6-
month follow up.  
Kiefer 2015 
(73) 
76 Alcohol dependence 9/9/9 50 No differences in 
improvement 
between DCS and 
PBO group on 
subjective outcome 
measures at post-
treatment. PBO 
group displayed 
higher fMRI 
activation than DCS 
group in brain 
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regions associated 
with negative 
outcomes. 
MacKillop 
2015 (74) 
37 Alcohol use disorder 4/2/2 50 DCS group displayed 
greater 
improvements than 
PBO group on 
session-specific 
measures and post-
treatment outcomes 
but not 3-week 
follow up.  
Schizophreniab           
Gottlieb 2011 
(96) 
21 Schizophrenia/schizoaffective 2/2/2 50 No differences in 
improvement 
between DCS and 
PBO on main 
outcome measures at 
post-treatment. 
Significant order 
effectsc; DCS first 
displayed greater 
improvements than 
PBO first on some 
outcomes at post-
treatment (moderate-
large effects). 
Cain 2014 (97) 40 Schizophrenia 24-40/8d 50 DCS group displayed 
greater 
improvements than 
PBO on one 
outcome, while PBO 
displayed greater 
improvement than 
DCS on another. 
Some evidence of 
more improvement 
for subjects with 
more severe 
pretreatment 
symptoms. 
Anorexia 
Nervosa 
          
Levinson 2015 
(76) 
36 Anorexia nervosa 4/4/3 250 DCS group displayed 
greater 
improvements than 
PBO on main 
outcome measure at 
post-treatment but 
not 1-month follow 
up.  
Running head: D-CYCLOSERINE AUGMENTATION OF EXTINCTION LEARNING  Otto  33 
 
Notes. PBO = placebo  aAll studies administered DCS prior to CBT sessions, except for the designated study, 
which administered DCS immediately after session; bSee supplemental information for discussion of the 
application of DCS to therapeutic learning in schizophrenia; cWithin-participant cross-over design; dThis study did 
not utilize exposure but utilized a "Brain Fitness" cognitive remediation program which took place 3-5x/week 
across 8 weeks. 
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